Decibel Therapeutics to Present at the Barclays Global Healthcare Conference
Decibel Therapeutics (Nasdaq: DBTX) will present at the Barclays Global Healthcare Conference on March 11, 2021, at 9:10 a.m. ET, as announced by CEO Laurence Reid, Ph.D.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Decibel Therapeutics (Nasdaq: DBTX) will present at the Barclays Global Healthcare Conference on March 11, 2021, at 9:10 a.m. ET, as announced by CEO Laurence Reid, Ph.D. A live webcast will be available on the Decibel Therapeutics website, with an archived replay accessible for 90 days post-event. The company focuses on innovative treatments for hearing and balance disorders, leveraging a proprietary platform to advance gene therapies. Notably, their lead program, DB-OTO, aims to address congenital hearing loss.
Details
News Market Reaction – DBTX
The recorded move for DBTX in the trading session of this news was -2.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 9:10 a.m. ET.
A live webcast of the presentation may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the company’s website for approximately 90 days following the presentation.
About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.
Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200
Media Contact:
Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.